CXCL12 and Hodgkins lymphoma: We also tested the effect of the high-affinity CXCL12/CXCR4 inhibitor BTK140 (4F-benzoyl-TN14003) on DLBCL cells in vitro, which not only inhibits CXCL12/CXCR4 mediated adhesion and migration [36], overcomes stromal cells-mediated chemoresistance, but also has direct cytotoxic activities in non-Hodgkin lymphoma cell lines, leukemic and multiple myeloma cells in a CXCR4-dependent and dose-dependent manner [29,37].